Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) (PAR-22-028)

Sponsor: National Institute of Neurological Disorders and Stroke.

Award: Funds are not awarded; this FOA is to provide investigators with a mechanism to access contract research/medical organizations and subject matter experts within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): Promoting research to understand vascular contributions to cognitive impairment and dementia (VCID) (NOT-HL-23-002)

Sponsor: National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute of Neurological Disorders and Stroke

Due Date: This notice applies to application receipt dates on or after February 5, 2022 and subsequent receipt dates through May 8, 2025.

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) (PAR-21-237)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple dates, see announcement.

Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) (PA-21-219)

Sponsor: National Institutes of Health

Due Date: Multiple dates, see announcement.

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed) (PAR-21-032)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.